MedTrace Logo

GSK1120212 Rollover Study

NCT01376310 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2019-02-19

Study results available
· View outcomes & findings →

Summary

This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.

Conditions

Interventions

DRUG

GSK1120212

up to 2 mg/day

DRUG

Docetaxel + GSK1120212

dose as defined in the dose escalation protocol.

DRUG

Erlotinib + GSK1120212

dose as defined in the dose escalation protocol.

DRUG

Pemetrexed + GSK1120212

dose as defined in the dose escalation protocol

DRUG

Carboplatin + GSK1120212

dose as defined in the dose escalation protocol

DRUG

Nab-paclitaxel + GSK1120212

dose as defined in the dose escalation protocol

DRUG

Gemcitabine + GSK1120212

dose as defined in the dose escalation protocol

DRUG

Everolimus + GSK1120212

dose as defined in the dose escalation protocol

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-02
Primary Completion
2018-01-18
Completion
2018-01-18
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Netherlands
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376310 on ClinicalTrials.gov